Edesa Biotech Ano de IPO
Qual é o Ano de IPO de Edesa Biotech?
O Ano de IPO de Edesa Biotech, Inc. é 2010
Qual é a definição de Ano de IPO?
A oferta pública inicia (OPI)l é um tipo de oferta pública em que as ações de uma empresa geralmente são vendidas a investidores institucionais que, por sua vez, vendem para o público em geral, em uma bolsa de valores, pela primeira vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Ano de IPO de empresas na Setor Health Care em NASDAQ em comparação com Edesa Biotech
O que Edesa Biotech faz?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Empresas com ano de ipo semelhantes a Edesa Biotech
- Chigo tem Ano de IPO de 2009
- Jade Road Investments tem Ano de IPO de 2009
- Equity Metals tem Ano de IPO de 2009
- Kerr Mines tem Ano de IPO de 2009
- China e-Wallet Payment tem Ano de IPO de 2009
- SQS India BFSI tem Ano de IPO de 2009
- Edesa Biotech tem Ano de IPO de 2010
- Broken Hill Prospecting tem Ano de IPO de 2011
- Apollo Global Management Inc tem Ano de IPO de 2011
- Hipo Resources tem Ano de IPO de 2011
- Cogra 48 SA tem Ano de IPO de 2011
- New Mountain Finance Corp tem Ano de IPO de 2011
- Marfrig Global Foods SA tem Ano de IPO de 2011